Harmony Biosciences PE ratio HRMY

Share price divided by earnings per share over the last twelve months, since 2021.

Today, Oct 23, 2026: 11.7×
5-year median: 13.8×
Against its 5-year history: 24th; percentile: 0 is its lowest day, 100 its highest
5-year range: 5.9× to 220×
Peer median: 15.7×

Harmony Biosciences' PE ratio is 11.7× as of Oct 23, 2026: a share price of $36.13 against $3.09 of earnings per share over the last twelve months.

That is below its 5-year median of 13.8×, lower than on 76% of days in the last 5 years.

Over that time it ranged from 5.9× in Oct 2023 to 220× in Dec 2021.

The median for 10 large drugmakers of a similar size is 15.7×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	11.7×	9.2×	15.0×
2025	12.0×	8.4×	18.5×
2024	16.2×	12.6×	20.1×
2023	13.1×	5.9×	21.0×
2022	21.5×	21.5×	192×
2021	213×	140×	220×

Against its peers

Companies in Drug Manufacturers - General nearest Harmony Biosciences' size, closest first, today.

Company	PE ratio
HRMYHarmony Biosciences	11.7×
PBHPrestige Consumer Healthcare	13.4×
ANIPANI Pharmaceuticals	15.4×
NRIXNurix Therapeutics	11.0×
PAHCPhibro Animal Health	15.9×
ANABAnaptysbio	10.7×
PCRXPacira BioSciences	104×
OGNOrganon	17.9×
OMEROmeros	10.9×
LQDALiquidia	30.7×
ARQTArcutis Biotherapeutics	142×
Peer median	15.7×

Where Harmony Biosciences ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Harmony Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.